AnaptysBio raises $40m for Phase II studies
This article was originally published in Scrip
Executive Summary
San Diego-based AnaptysBio has several antibody discovery partnerships with pharmaceutical and biotechnology companies, but the firm will use its $40m in Series D venture capital financing to run Phase II clinical trials for two of its own therapeutic candidates.
You may also be interested in...
IPO Update: Three Biopharma Offerings In January Contrast With Last Year’s Slow Start
AnaptysBio, Jounce and ObsEva were the first three companies to go public in 2017 – all in January – while no therapeutics firms went public in January 2016. The difference? Better US biopharma stock performance.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.